Johnson & Johnson (NYSE:JNJ) CAO Robert J. Decker Sells 16,928 Shares

Johnson & Johnson (NYSE:JNJ – Get Rating) CAO Robert J. Decker sold 16,928 shares of the stock in a transaction on Friday, November 18th. The shares were sold at an average price of $175.00, for a total value of $2,962,400.00. Following The sale, the chief accounting officer now owns 15,473 shares in the company, valued at approximately $2,707,775. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Johnson & Johnson Stock Down 0.1 %

Shares of JNJ traded down $0.23 during midday trading on Monday, reaching $175.97. 5,705,903 shares of the stock were exchanged, compared to its average volume of 7,385,839. The Johnson & Johnson has a 52 week low of $155.72 and a 5 week high of 9. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37. The company’s 50 day moving average is $167.84 and its two-hundred day moving average is $171.29. The company has a market capitalization of $460.07 billion, a P/E ratio of 24.54, a PEG ratio of 3.49 and a beta of 0.57.

Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its quarterly earnings results on Tuesday, October 18th. The company reported $2.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.49 by $0.06. Johnson & John had a return on equity of 35.37% and a net margin of 19.95%. The business had revenue of $23.79 billion for the quarter, compared to the consensus estimate of $23.44 billion. During the same quarter in the prior year, the company earned $2.60 EPS . The business’s revenue was up 1.9% compared to the same quarter last year. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.04 earnings per share for the current year.

Johnson & Johnson announced that its Board of Directors has authorized a share repurchase plan on Wednesday, September 14th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the company to buy up to 1.2% mark of through its shares open purchases. Shares buyback plans are usually an indication that the company’s board of directors believes its shares are undervalued.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 6th. Investors of record on Tuesday, November 22nd will be given a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis of and a y 2.57%. The ex-dividend date of this dividend is Monday, November 21st. Johnson & Johnson’s payout ratio is currently 62.95%.

Institutional Investors Weigh In On Johnson & Johnson

A number of institutional investors have recently added to or reduced their stakes in JNJ. Price T Rowe Associates Inc. MD boosted its position in Johnson & Johnson by 18.9% during the second quarter. Price T Rowe Associates Inc. MD now owns of 24,622,795 shares the company’s stock valued at $4,370,793,000 after purchasing an additional 3,912,430 shares in the last quarter. Vanguard Group Inc. raised its stake in Johnson & Johnson by 1.4% in the first quarter. Vanguard Group Inc. now owns 238,141,110 shares of the company’s stock valued at $42,205,749,000 after buying an additional 3,358,478 shares during the last quarter. FMR LLC raised its stake in Johnson & Johnson by 20.8% in the second quarter. FMR LLC now owns 18,725,049 shares of the company’s stock valued at $3,323,883,000 after buying an additional 3,229,032 shares during the last quarter. GQG Partners LLC raised its stake in Johnson & Johnson by 64.4% in the first quarter. GQG Partners LLC now owns 6,501,761 shares of the com pany’s stock valued at $1,151,931,000 after buying an additional 2,547,378 shares during the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its stake in Johnson & Johnson by 52.2% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 6,102,999 shares of the company’s stock valued at $1,083,329,000 after buying an additional 2,093,392 shares during the last quarter. Institutional investors own 68.59% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Sanford C. Bernstein decreased their price target on Johnson & Johnson from $194.00 to $190.00 in a report on Wednesday, October 19th. Raymond James cut their price objective on Johnson & Johnson from $192.00 and Johnson from $192.00 to $18 an “outperform” rating on the stock in a research report on Wednesday, October 19th. StockNews.com initiated coverage on Johnson & Johnson in a research report on Wednesday, October 12th. They issued a “strong-buy” rating on the stock. Barclays initiated coverage on Johnson & Johnson in a research report on Monday, October 17th. They issued an “equal weight” rating and a $175.00 price objective on the stock. Finally, Bank of America cut their price objective on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a research report on Friday, October 14th. Seven analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating t o the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $181.33.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby INTER ISTER brands; oral care under the Lbrs skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or out comments about this story contact@marketbeat.com.

Before you consider Johnson & Johnson, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before market the broader on… and Johnson & Johnson wasn’t on the list.

While Johnson & Johnson currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here